Literature DB >> 21148489

Emerging influenza antiviral resistance threats.

Frederick G Hayden, Menno D de Jong.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 21148489      PMCID： PMC3086431          DOI： 10.1093/infdis/jiq012

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  55 in total

1.  Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors.

Authors:  Andrés Pizzorno; Xavier Bouhy; Yacine Abed; Guy Boivin
Journal:  J Infect Dis       Date:  2011-01-01       Impact factor: 5.226

2.  Dual resistance to adamantanes and oseltamivir among seasonal influenza A(H1N1) viruses: 2008-2010.

Authors:  Tiffany G Sheu; Alicia M Fry; Rebecca J Garten; Varough M Deyde; Thein Shwe; Lesley Bullion; Patrick J Peebles; Yan Li; Alexander I Klimov; Larisa V Gubareva
Journal:  J Infect Dis       Date:  2011-01-01       Impact factor: 5.226

3.  Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice.

Authors:  Donald F Smee; Brett L Hurst; Min-Hui Wong; Kevin W Bailey; John D Morrey
Journal:  Antimicrob Agents Chemother       Date:  2009-03-09       Impact factor: 5.191

4.  Prolonged influenza virus infection during lymphocytopenia and frequent detection of drug-resistant viruses.

Authors:  Jairo Gooskens; Marcel Jonges; Eric C J Claas; Adam Meijer; Aloys C M Kroes
Journal:  J Infect Dis       Date:  2009-05-15       Impact factor: 5.226

5.  Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice.

Authors:  Natalia A Ilyushina; Erich Hoffmann; Rachelle Salomon; Robert G Webster; Elena A Govorkova
Journal:  Antivir Ther       Date:  2007

6.  Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice.

Authors:  Natalia A Ilyushina; Alan Hay; Neziha Yilmaz; Adrianus C M Boon; Robert G Webster; Elena A Govorkova
Journal:  Antimicrob Agents Chemother       Date:  2008-08-25       Impact factor: 5.191

7.  Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States.

Authors:  Nila J Dharan; Larisa V Gubareva; John J Meyer; Margaret Okomo-Adhiambo; Reginald C McClinton; Steven A Marshall; Kirsten St George; Scott Epperson; Lynnette Brammer; Alexander I Klimov; Joseph S Bresee; Alicia M Fry
Journal:  JAMA       Date:  2009-03-02       Impact factor: 56.272

8.  Morbidity and mortality associated with nosocomial transmission of oseltamivir-resistant influenza A(H1N1) virus.

Authors:  Jairo Gooskens; Marcel Jonges; Eric C J Claas; Adam Meijer; Peterhans J van den Broek; Aloyj M Kroes
Journal:  JAMA       Date:  2009-03-02       Impact factor: 56.272

9.  Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial.

Authors:  Xavier Duval; Sylvie van der Werf; Thierry Blanchon; Anne Mosnier; Maude Bouscambert-Duchamp; Annick Tibi; Vincent Enouf; Cécile Charlois-Ou; Corine Vincent; Laurent Andreoletti; Florence Tubach; Bruno Lina; France Mentré; Catherine Leport
Journal:  PLoS Med       Date:  2010-11-02       Impact factor: 11.069

10.  Enzymatic properties of the neuraminidase of seasonal H1N1 influenza viruses provide insights for the emergence of natural resistance to oseltamivir.

Authors:  Marie-Anne Rameix-Welti; Vincent Enouf; Frédérique Cuvelier; Patricia Jeannin; Sylvie van der Werf
Journal:  PLoS Pathog       Date:  2008-07-25       Impact factor: 6.823
View more
  70 in total

1.  Mapping the pulmonary environment of animals protected from virulent H1N1 influenza infection using the TLR-2 agonist Pam₂Cys.

Authors:  Edin J Mifsud; Amabel C L Tan; Patrick C Reading; David C Jackson
Journal:  Immunol Cell Biol       Date:  2015-08-14       Impact factor: 5.126

2.  Discovery of novel dual inhibitors of the wild-type and the most prevalent drug-resistant mutant, S31N, of the M2 proton channel from influenza A virus.

Authors:  Jizhou Wang; Chunlong Ma; Jun Wang; Hyunil Jo; Belgin Canturk; Giacomo Fiorin; Lawrence H Pinto; Robert A Lamb; Michael L Klein; William F DeGrado
Journal:  J Med Chem       Date:  2013-03-27       Impact factor: 7.446

3.  Timely Antiviral Administration During an Influenza Pandemic: Key Components.

Authors:  Lisa M Koonin; Anita Patel
Journal:  Am J Public Health       Date:  2018-09       Impact factor: 9.308

4.  Combination antiviral therapy for influenza: predictions from modeling of human infections.

Authors:  Alan S Perelson; Libin Rong; Frederick G Hayden
Journal:  J Infect Dis       Date:  2012-03-23       Impact factor: 5.226

Review 5.  Newer influenza antivirals, biotherapeutics and combinations.

Authors:  Frederick G Hayden
Journal:  Influenza Other Respir Viruses       Date:  2013-01       Impact factor: 4.380

6.  The H275Y neuraminidase mutation of the pandemic A/H1N1 influenza virus lengthens the eclipse phase and reduces viral output of infected cells, potentially compromising fitness in ferrets.

Authors:  Lady Tatiana Pinilla; Benjamin P Holder; Yacine Abed; Guy Boivin; Catherine A A Beauchemin
Journal:  J Virol       Date:  2012-07-25       Impact factor: 5.103

Review 7.  The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives.

Authors:  Lukas Wanka; Khalid Iqbal; Peter R Schreiner
Journal:  Chem Rev       Date:  2013-02-25       Impact factor: 60.622

8.  Structure-aided drug development of potential neuraminidase inhibitors against pandemic H1N1 exploring alternate binding mechanism.

Authors:  Khushboo D Malbari; Anand S Chintakrindi; Lata R Ganji; Devanshi J Gohil; Sweta T Kothari; Mamata V Joshi; Meena A Kanyalkar
Journal:  Mol Divers       Date:  2019-02-01       Impact factor: 2.943

9.  Predicting dual-targeting anti-influenza agents using multi-models.

Authors:  Yu Wang; Hu Ge; Yali Li; Yufang Xie; Yingyan He; Mengyan Xu; Qiong Gu; Jun Xu
Journal:  Mol Divers       Date:  2014-10-02       Impact factor: 2.943

10.  Design and expeditious synthesis of organosilanes as potent antivirals targeting multidrug-resistant influenza A viruses.

Authors:  Yanmei Hu; Yuanxiang Wang; Fang Li; Chunlong Ma; Jun Wang
Journal:  Eur J Med Chem       Date:  2017-04-20       Impact factor: 6.514
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.